Navigation Links
Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
Date:9/12/2007

September 11, 2007

WASHINGTON, Sept. 12 /PRNewswire-USNewswire/ -- The following is a statement by KCP Chairman Dr. Edward Jones:

Yesterday's FDA Advisory Committee meeting underscores the many considerations that must be factored in to policymaking related to anemia treatment in patients suffering from chronic kidney disease. The kidney community salutes FDA for working with scientists, practicing nephrologists, and other members of the medical community to achieve a consensus on hemoglobin and dosing levels for erythropoietin-stimulating agents (ESAs) based on different patient populations. The community is unified in its belief that patient quality of care and quality of life must be taken into account as physicians treat anemia in kidney patients. Patients with chronic kidney disease and those on dialysis depend on ESAs to stimulate red blood cell production in their bodies.

Anemia-management drugs have been well demonstrated to improve quality of life for kidney patients and provide significant medical benefits. Unlike patients with cancer, patients with chronic kidney disease are permanently affected by anemia, which in turn affects their ability to engage in day-to- day activities that non-patients take for granted -- caring for their families, holding a job, and going to school. Without ESA therapy, ESRD patients may develop hemoglobin levels that are dangerously low. Before ESAs were available, blood transfusions were required in most kidney patients. Transfused patients often suffered from heart failure, iron overload, and other chronic problems.

Several studies have demonstrated improvement in the morbidity and mortality of patients with kidney disease and kidney failure by the appropriate management of their anemia. After extensive review of the results of six new studies, a National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) work group updated its Clinical Practice Guidel
'/>"/>

SOURCE Kidney Care Partners
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Obama Statement on Bush Veto of Stem Cell Bill
3. Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England
4. New Position Statement from The North American Menopause Society Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in Postmenopausal Women
5. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
6. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
7. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
8. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
9. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
10. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
11. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... -- Neuralstem, Inc. (NYSE MKT: CUR) today reported that ... presented updated Phase I data from its spinal cord-derived ... of amyotrophic lateral sclerosis (ALS or Lou ... medical symposium in Bucharest, Romania , ... in Stem Cell Therapy," Dr. Feldman outlined the design ...
(Date:5/20/2013)... CHICAGO, Ill. , May 20, 2013 /PRNewswire/ ... the initiation of a Phase 3 clinical study ... to assess the effects of the investigational compound ... progression of kidney disease in patients with stage ... type 2 diabetes.  SONAR is a large, multinational, ...
(Date:5/20/2013)... , May 20, 2013 With herbal medicines ... available from the U.S. Pharmacopeial Convention (USP) will provide ... of the herbal ingredients used in these products. Today, ... in the new Herbal Medicines Compendium ( ... at hmc.usp.org . HMC ...
Breaking Medicine Technology:Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 2New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 3
(Date:5/20/2013)... The automated external defibrillator market ... categories - semi-automated and fully automated defibrillators. Based ... categories, namely, hospitals, pre-hospital, public access, alternate care, ... Automated external defibrillators play an important role in ... Considering the life-saving potential of AEDs, legislations requiring ...
(Date:5/20/2013)... new healthcare bill proposes to have major ramifications in ... all the conditions were to be implemented or have ... 2014 to show anything. , According to Health ... forward to implement the health care law and establishing ... and West Virginia. HHS will continue to provide the ...
(Date:5/20/2013)... 20, 2013 Eben Pagan's ... the public creating a frenzy among business owners ... elite business training. WealthSpringMarketing.com's Tiffany Hendricks has published ... an exclusive bonus. , "Eben Pagan is a ... training to individuals serious about success," reports Hendricks. ...
(Date:5/20/2013)... According to a May 6, 2013 CBS ... Salons,” tanning salons in the US may soon ... Administration wants to see cancer warnings on indoor tanning ... of eighteen for the use of indoor tanning and sun ... has become increasingly common over the last few decades (Go ...
(Date:5/20/2013)... Lake City, UT (PRWEB) May 20, 2013 ... named one of Select Health’s Select 25 winners ... receive $2500 from Select Health. Know Greater Heroes is a ... local elementary schools to teach children how to eat right, ... student athletes participate in the Know Greater Heroes program each ...
Breaking Medicine News(10 mins):Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 2Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 3Health News:Review of Health Bill Impact in 2014 2Health News:Review of Health Bill Impact in 2014 3Health News:Eben Pagan's Accelerate: Review and Bonus Released By WealthSpringMarketing.com 2Health News:Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs 2Health News:SLCC Know Greater Heroes Program Named to Select 25 2Health News:SLCC Know Greater Heroes Program Named to Select 25 3
... Hologic, Inc. (Nasdaq: HOLX ) today announced that Glenn ... Global Healthcare Unplugged Conference in New York City on Tuesday, September ... Interested parties are invited to listen to a live audio ... company,s website at www.hologic.com/investor . An archive of ...
... , , , ... (Nasdaq: ZIXI ), the leader in email encryption services, today ... is a two-year extension of Humana,s original agreement which has now spanned ... ZixCorp licenses bringing the total to 36,000. , , ...
... in the September 2009 issue of the Journal of ... life prior to treatment can help predict the overall survival ... For those with advanced stage NSCLC, the median overall ... of patients surviving past the one year mark. To better ...
... study, approximately 20% of U.S. soldiers returning from Iraq ... substantial number with post-traumatic stress disorder (PTSD), and the ... unacceptable to Army commanders and the soldiers, families. ... doctors will now be able to forecast a soldier,s ...
... discounts, special promotions lead to greater alcohol consumption, study shows ... college bars lead to more intoxicated students and more health ... news that college students drink and the results can be ... the impact of drink discounts at college bars and found ...
... , , , WASHINGTON, Sept. ... flu, or H1N1 outbreak, in a recent article . , ... of the Mexican government in the fields of public awareness, rapid ... , The article noted "Mexico,s most effective action ...
Cached Medicine News:Health News:Zix Corporation and Humana Renew and Expand Exclusive Agreement 2Health News:Keeping the suicidal soldier alive 2Health News:College Students Get More Drunk When Drinks Are Cheap 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: